Table 1.
Characteristics of the included studies.
| Resources | Cohort | Country/region | Drug | Total patient-years | Number of women (%) | NOS |
|---|---|---|---|---|---|---|
| Shalom et al. (6) | The Psoriasis Longitudinal Assessment (PSOLAR) | Global | Methotrexate | 1,463 | 52.5 | 6 |
| Failla et al. (7) | University of Liège hospital medical record database | Belgium | Etanercept, adalimumab, infliximab, rituximab, ustekinumab | 4,206 | Unknown | 6 |
| Dreiher et al. (8) | The database of Clalit Health Services (CHS) | Israel | Alefacept, efalizumab | 51 | 33 | 7 |
| Kalb et al. (9) | The Psoriasis Longitudinal Assessment (PSOLAR) | Global | Etanercept, adalimumab, infliximab, ustekinumab | 17,099 | 43.2 | 8 |
| Shalom et al. (10) | The database of Clalit Health Services (CHS) | Israel | Etanercept, adalimumab, infliximab, ustekinumab, methotrexate | 10008.6 | 52.6 | 8 |
NOS, Newcastle–Ottawa Scale.